The virus finds its victims among the very young and sickens them severely, but it kills the old.
A familiar constellation of respiratory viruses — influenza A, rhinovirus, and RSV — has spread across all 27 Brazilian states in 2026, pushing the nation's public health system into a posture of collective alert. Since January, more than 77,000 cases of acute severe respiratory syndrome have been recorded, with Fiocruz projecting the wave has not yet crested. As is so often true of respiratory illness, the burden falls unevenly: the very young are struck hardest by infection, while the elderly bear the weight of mortality — a reminder that vulnerability is not uniform, and that protection must be deliberate.
- Every single Brazilian state has crossed into alert or high-risk territory, signaling that this is no longer a regional crisis but a nationwide respiratory emergency.
- More than 77,000 SRAG cases have accumulated since January, with laboratory backlogs and Fiocruz's own projections suggesting the worst is still ahead.
- Infants under two are being hospitalized at the highest rates, while adults over 65 account for the majority of deaths — two vulnerable populations facing the same surge in very different ways.
- Vaccination has been identified as the single most critical intervention, with a particular urgency around pregnant women receiving the RSV vaccine to shield their newborns through transferred immunity.
- Health authorities are now in a race to reach the elderly, young children, and immunocompromised populations before the surge peaks — a window that is narrowing with each passing week.
Brazil is confronting a sweeping respiratory illness surge that has now reached every corner of the country. On Wednesday, the Oswaldo Cruz Foundation — Fiocruz — released an epidemiological bulletin confirming that all 27 states have entered either alert or high-risk territory for acute severe respiratory syndrome, known as SRAG. The driving forces are influenza A, rhinovirus, and respiratory syncytial virus, circulating with unusual intensity this year.
Since January, Brazil has recorded 77,153 SRAG cases, nearly half of which tested positive for one of the viruses under surveillance. A laboratory backlog of nearly 7,000 pending results reflects the sheer volume of illness moving through the health system — and Fiocruz's models project the surge will keep climbing.
The illness does not strike all ages equally. Children under two are the most frequently hospitalized group, bearing the heaviest burden of influenza-linked SRAG. Yet the deaths tell a different story: the elderly — those over 65 — account for the majority of fatalities, with influenza A alone responsible for nearly half of recent deaths. RSV, rhinovirus, and COVID-19 account for significant shares as well.
Fiocruz researcher Tatiana Portella has identified vaccination as the essential defense, with particular urgency for the elderly, young children, and the immunocompromised. For RSV, the strategy takes an indirect but elegant form: vaccinating pregnant women so that antibodies transfer to their newborns, providing a protective shield during the first six months of life. For influenza and COVID-19, direct vaccination of at-risk groups remains the priority. The challenge now is reaching these populations before the wave peaks — a race already underway in every state.
Brazil is in the grip of a respiratory illness surge that has now reached every corner of the country. On Wednesday, the Oswaldo Cruz Foundation—Fiocruz, the nation's premier public health research institute—released its latest epidemiological bulletin with a stark finding: all 27 states have crossed into either alert or high-risk territory for acute severe respiratory syndrome, known as SRAG. The culprits are familiar viruses circulating with unusual force this year: influenza A, rhinovirus, and respiratory syncytial virus, or RSV.
Since January, Brazil has recorded 77,153 cases of SRAG. Nearly half—37,153 cases—tested positive for one of the respiratory viruses under surveillance. Another 27,841 came back negative. About 6,934 remain pending laboratory confirmation, a backlog that underscores the volume of illness moving through the health system. The numbers alone convey scale, but they mask a more troubling pattern: Fiocruz's models project the surge will continue climbing in the weeks ahead.
The illness is not striking all ages equally. Children under two years old bear the heaviest burden of infection from influenza-linked SRAG—they are the group most frequently hospitalized with the syndrome. Yet the deaths tell a different story. Among the deceased in the past four weeks, nearly half died from influenza A, and eight percent from influenza B. But the elderly—those over 65—account for the majority of fatalities. In other words, the virus finds its victims among the very young and sickens them severely, but it kills the old. For RSV, rhinovirus, and COVID-19 combined, the proportions shift: 16.6 percent of deaths involved RSV, 16.9 percent rhinovirus, and nine percent COVID-19.
Public health officials have settled on a single intervention as the primary defense: vaccination. Tatiana Portella, a researcher with Fiocruz's InfoGripe bulletin and scientific computing program, frames it plainly—vaccination is the essential tool to prevent severe illness and death from the major respiratory viruses driving SRAG. The message carries particular urgency for three groups: the elderly, young children, and anyone living with chronic illness or immunocompromise.
The RSV vaccine presents a novel wrinkle in Brazil's immunization strategy. The shot is administered to pregnant women, who then produce antibodies and transfer them to their infants in utero and through breast milk. This maternal antibody shield protects newborns during their first six months of life, the window when RSV poses the greatest risk. It is a form of borrowed immunity, temporary but critical. For influenza and COVID-19, the approach is more conventional: direct vaccination of at-risk populations, with emphasis on keeping doses current as immunity wanes. The challenge now is reaching these groups before the surge peaks—a race against a virus that has already claimed ground in every state.
Citações Notáveis
Vaccination is the essential tool to prevent severe illness and death from the major respiratory viruses driving SRAG, particularly for the elderly, young children, and those with chronic illness.— Tatiana Portella, Fiocruz researcher
RSV vaccine is administered to pregnant women so they produce and transmit antibodies to their babies, protecting them during their first six months of life.— Tatiana Portella, Fiocruz researcher
A Conversa do Hearth Outra perspectiva sobre a história
Why are children under two so much more vulnerable to infection, but the elderly more likely to die?
The young immune system is still learning to recognize these viruses. It mounts a vigorous response—which is why they get sick—but they have reserves of resilience the elderly lack. An older body, especially one worn down by years of other illness, simply cannot weather the same infection.
So vaccination of pregnant women for RSV is a workaround for the fact that babies can't be vaccinated directly?
Exactly. A newborn's own immune system isn't mature enough to respond well to a vaccine. But a pregnant woman can be vaccinated, and her body does the work of making antibodies and passing them down. It's protection by proxy, but it works for those critical first months.
If 77,000 cases have been reported since January, and we're only in June, what does the projection for coming weeks actually mean?
It means the curve hasn't flattened. The virus is still accelerating. Every state is now in alert or high-risk status, which suggests the healthcare system is already under strain. The projection is a warning that strain will deepen.
Why influenza A specifically? Is it a new strain?
The source doesn't say it's new. It's just circulating with more force than usual this year. That happens sometimes—a virus finds conditions favorable, spreads efficiently, and suddenly you have a surge. The why is harder to pin down without more data.
What happens to the people still waiting for lab results?
They're in limbo clinically. They're sick enough to be counted, sick enough to be hospitalized, but the health system doesn't yet know which virus is causing their illness. That delays targeted treatment and makes it harder to track which pathogen is doing the most damage.